|Systematic (IUPAC) name|
|ATC code||C09CA05 (WHO)|
|Molar mass||411.459 g/mol[[Script error: No such module "String".]]|
Tasosartan is an angiotensin II receptor antagonist.
It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|30px||This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it.|